MISSION-ZERO-TECH
11.12.2023 13:01:34 CET | Business Wire | Press release
Mission Zero Technologies:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211608638/en/
Mission Zero Technologies' direct air capture technology sits inside a 20-foot shipping container for easy mobility and modular scaling, so that it can be deployed around the world. This small footprint allows it to be easily incorporated into a customer's site — and moved at a later point, if need be. (Photo: Business Wire)
- Carbon removal technology developer Mission Zero Technologies (MZT) has turned on the UK’s first direct air capture (DAC) plant, which efficiently removes CO₂ from the atmosphere using renewable energy and water.
- The plant was bought by the University of Sheffield’s Translational Energy Research Centre (TERC) for a first-of-a-kind UK project validating Sustainable Aviation Fuel (SAF) made from air to decarbonise UK aviation.
- The plant is one of two commercially-financed DAC systems in the world, establishing the UK as a front runner within the burgeoning global DAC industry.
- DAC is globally recognised by the Intergovernmental Panel on Climate Change (IPCC) as a critical technology for humanity to meet its 1.5°C obligations.
The plant at a glance
On a mission to reinvent the world’s relationship with carbon, MZT have deployed their first commercially-financed DAC system in the UK seven months after signing the contract. The plant was sold to the University of Sheffield’s TERC, a world-leading zero-carbon energy research institution. TERC will use MZT’s technology to validate the end-to-end production of jet fuel made from atmospheric carbon, certifying it so that it can be brought to market.
MZT’s energy-efficient electrochemical DAC technology recovers CO₂ from the atmosphere using electricity and water. The remotely-operated plant will run on solar power generated on site to recover 50 tonnes per year of high-purity CO₂ from the air. MZT’s versatile DAC technology provides a plug and play source of sustainable carbon on demand for both sustainable use and permanent removal. Designed for rapid scaling, it leverages mature off-the-shelf components in a modular design that can be integrated with load-variable renewable grids.
UK industrial climate leadership
A watershed moment for the UK’s DAC and SAF industries, the plant reinforces the UK’s position as an international climate leader accelerating critical solutions to help deliver Net Zero. DAC is widely seen as the only technology capable of providing a sustainable carbon feedstock to help the UK government meet its mandate for 10% SAF jet fuel by 2030. This first-of-a-kind UK DAC-to-jet fuel project will provide project financiers and developers with the analysis required to scale a UK SAF ecosystem. By proving DAC’s readiness for industrial scale, it will also pave the way for more fossil-dependent industries to rapidly decarbonise.
“We’re thrilled to be delivering our first ever DAC plant on home soil with the University of Sheffield,” said MZT’s CEO, Dr Nicholas Chadwick. “DAC is a multi-use technology able to drive deep industrial decarbonisation and permanent carbon removal. Through pioneering partnership, we’re already realising that potential.”
Professor Mohamed Pourkashanian, Managing Director of TERC, said: “This installation is hugely exciting for us, and for the world, as we discover more about the potential for decarbonised industrial processes and air transport using novel DAC technology. TERC’s capabilities in processing captured carbon in order to transform it has made it an ideal location for the first DAC plant. We’re excited to work closely with MZT on this project and other world-leading activities.”
About Mission Zero Technologies:
Based in London, UK, Mission Zero Technologies is reinventing carbon for a thriving planet. Since 2020, the team has rapidly pioneered high-efficiency Direct Air Capture (DAC) technology to remove historic CO₂ emissions from the atmosphere anywhere at any scale. Backed by Breakthrough Energy Ventures, the XPRIZE foundation, Anglo American, Stripe, and the UK Government, Mission Zero has moved from lab to commercial plants in under three years to rapidly empower carbon removal and utilisation pathways. Follow their mission at www.missionzero.tech.
About the Translational Energy Research Centre:
The Translational Energy Research Centre (TERC) is a world-leading pilot-scale research centre, working with industry to test and develop green energy solutions for a decarbonised future. It is one of the largest and best-equipped zero-carbon energy research and development facilities in Europe. Based at the University of Sheffield and forming part of its Energy Institute, TERC works with industrial and academic partners to find solutions to critical energy challenges through world-class research and dedicated testing and demonstration. For more information, visit: terc.ac.uk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231211608638/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
